| 摘要 |
FIELD: medicine, immunobiotechnology. SUBSTANCE: invention relates to monoclonal antibody (MKAT) raised to human CD23. MKAT involves antigen-binding segment specifically binding with human CD23 and constant human segment gamma1 or gamma3. Antigen-binding segment is taken among antibody of primate, rodent and also from humanized antibody or it is a derivative of MKAT 5EB, 6G5 or 2C8. It is shown that MKAT inhibits production of IgE in vitro and its expression in vivo by inhibition of expression by B-cells. MKAT shows binding affinity in the range 0.01-1000 nM, in part, in the level 5 nM and 100 nM and able to suppress binding MKAT 5E8, 6G5 or 2C8 to human CD23 to human CD23. Invention describes pharmaceutical composition based on MKAT for treatment or prophylaxis of morbid state where suppression of IgE is desirable therapeutically or prophylactically and method of treatment or prophylaxis using this antibody. Invention provides possibility of the aim-directed regulation of production or exploitation of IgE in vitro and in vivo. EFFECT: valuable medicinal properties of antibody. 20 cl, 10 dwg |
